Salvage lymph node dissection in nonm... - Advanced Prostate...

Advanced Prostate Cancer

20,782 members25,886 posts

Salvage lymph node dissection in nonmetastatic castration-resistant PCA.

pjoshea13 profile image
3 Replies

New Mayo study below [1].

"To evaluate oncologic outcomes of patients with nonmetastatic, castration-resistant prostate cancer treated with salvage lymph node dissection (sLND) or androgen-deprivation therapy (ADT) for lymph nodes (LN)-only recurrence."

"Mean PSA reduction was significantly higher after sLND than ADT (62.8% vs. 17.7% ...)."

"... there was a trend toward a longer time to {biochemical recurrence} (13.3 vs. 6 months ...) and {radiological recurrence} (21.1 vs. 14.2 months ...) in sLND patients than ADT..."

"... Median time to {second line systemic therapies} was longer in the sLND group than ADT ..)"

Conclusion: "In patients with nonmetastatic, castration-resistant prostate cancer, sLND resulted in greater PSA decrease than ADT. We noted a nonstatistically significant trend toward longer time to {biochemical recurrence} and longer time to {radiological recurrence} for patients treated with sLND than ADT. Additionally, sLND may increase time to {second line systemic therapies} as compared to ADT."

-Patrick

[1] ncbi.nlm.nih.gov/pubmed/316...

Urol Oncol. 2019 Oct 22. pii: S1078-1439(19)30367-9. doi: 10.1016/j.urolonc.2019.09.016. [Epub ahead of print]

The role of salvage lymph node dissection in nonmetastatic castration-resistant prostate cancer: A single center experience.

Boeri L1, Sharma V2, Nehra A2, Kwon E2, Karnes RJ2.

Author information

1

Department of Urology, Mayo Clinic, Rochester, MN; Department of Urology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Electronic address: dr.lucaboeri@gmail.com.

2

Department of Urology, Mayo Clinic, Rochester, MN.

Abstract

OBJECTIVE:

To evaluate oncologic outcomes of patients with nonmetastatic, castration-resistant prostate cancer treated with salvage lymph node dissection (sLND) or androgen-deprivation therapy (ADT) for lymph nodes (LN)-only recurrence.

MATERIALS AND METHODS:

Retrospective analysis of 23 (51.1%) patients who underwent sLND and 22 (48.9%) men who received ADT for LN-only recurrence. Biochemical recurrence (BCR) was defined as prostate-specific antigen (PSA) >0.2 ng/ml with an increased trend and radiological recurrence (RAR) was defined as a positive imaging study after sLND or ADT. Second line systemic therapies (SST) were defined as any systemic therapy administered for progression. Predictors of BCR, RAR, and SST were assessed with Cox regression analyses.

RESULTS:

Mean PSA reduction was significantly higher after sLND than ADT (62.8% vs. 17.7%; P = 0.04). Clinical outcomes were not statistically different between the 2 groups. However, there was a trend toward a longer time to BCR (13.3 vs. 6 months; P = 0.2) and RAR (21.1 vs. 14.2 months, P = 0.09) in sLND patients than ADT. Median time to SST was longer in the sLND group than ADT (P = 0.04). Univariable Cox regression analyses showed that PSA doubling time and pT stage were associated with RAR and SST (all P < 0.05).

CONCLUSIONS:

In patients with nonmetastatic, castration-resistant prostate cancer, sLND resulted in greater PSA decrease than ADT. We noted a nonstatistically significant trend toward longer time to BCR and longer time to RAR for patients treated with sLND than ADT. Additionally, sLND may increase time to SST as compared to ADT.

Copyright © 2019 Elsevier Inc. All rights reserved.

KEYWORDS:

Androgen-deprivation therapy; Castration-resistant prostate cancer; Lymph nodes; Salvage lymph node dissection; Survival outcomes

PMID: 31653561 DOI: 10.1016/j.urolonc.2019.09.016

Written by
pjoshea13 profile image
pjoshea13
To view profiles and participate in discussions please or .
Read more about...
3 Replies
Graham49 profile image
Graham49

Patrick

Given that it is castration resistant PCa isn't it fairly obvious that ADT would not be very effective and cutting out would be more effective? Or Am I misunderstanding the situation?

pjoshea13 profile image
pjoshea13 in reply to Graham49

Graham,

Yes - CRPC implies first-line ADT failure in both arms of the study. So it seems that they compared surgery without ADT versus continuation of ADT.

I wonder what the mean time is between becoming CRPC & starting "second line systemic therapies".

-Patrick

GP24 profile image
GP24

In the full text they report that a mean of 4 affected lymph nodes were removed. This probably caused the drop in the PSA value.

Most non-metastatic CRPC patients show mets using a PSMA PET/CT:

urotoday.com/recent-abstrac...

You may also like...

Salvage lymph node dissection for nodal recurrent prostate cancer.

those considereing salvage lymph node treatment. We still do not know if dissection helps on long...

Recurrence after lymph node dissection / How best to stall PSA progression

active nodes. After the dissection my PSA dropped to a new low of .08, suggesting I had active...

Testosterone & Castration-Resistant PCa.

Testosterone in the Treatment of Castration-Resistant Prostate Cancer. Drazer MW1, Stadler WM....

Castration resistance

weeks ago. Just curious what other castration resistant prostate cancer warriors out there are...

Is my PCa becoming castrate resistant?

I am on ADT break. Three months ago my T was less than 20 and my psa was 0.104. Now my psa has...